Navigation Links
Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
Date:9/15/2008

BRIDGEWATER, N.J., and BRUSSELS, Belgium, Sept. 15 /PRNewswire/ -- Drais Pharmaceuticals, Inc. and Unibioscreen S.A. today announced that they have entered into a global agreement to develop and commercialize UNBS 5162, one of Unibioscreen's investigational drug and potential breakthrough treatments for cancer. UNBS 5162 was discovered by Unibioscreen and is currently in Phase I trials in the United States in cancer patients with advanced solid tumors or lymphoma.

"This is an important milestone for Drais as we focus on building a portfolio of novel therapeutics," said Dr. Donna L. Tempel, president and chief executive officer of Drais Pharmaceuticals. "Partnering with innovative companies like Unibioscreen is an important step towards implementing our strategy of in-licensing and developing novel therapeutic treatments that meet unmet medical needs."

Under the terms of the agreement, Unibioscreen will receive upfront, development and regulatory milestones payments up to $31 million, in addition to commercial milestone payments. The license grants exclusive rights to Drais to develop and commercialize UNBS 5162 worldwide.

Christiane Verhaegen, chief executive officer and chief financial officer of Unibioscreen commented: "Unibioscreen's deal with Drais is a key milestone for both the development of the drug candidate and for the company as it provides validation of Unibioscreen's promising pipeline of potential cancer treatments in addition to monetary benefits. We are confident that Drais' experienced team will maximize the progression of UNBS 5162 and believe this agreement will provide excellent value for both partners." Denis Biju-Duval, Head of ING Belgium Corporate Investments added: "The agreement illustrates the ability of Unibioscreen to successfully exploit its unique technology and know-how. Unibioscreen will continue to innovate in the oncology sector."

About UNBS 5162

UNBS 5162 is a novel anti-cancer naphthalimi
'/>"/>

SOURCE Drais Pharmaceuticals, Inc. and Unibioscreen S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Provides Update on Iloperidone
2. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
3. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
4. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
5. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
8. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
11. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... compares favorably with endoscopic resection for advanced disease, and ... SUNNYVALE, Calif., June 3 Results from ... Digestive Disease Week (DDW) in Chicago this week, revealing ... the HALO ablation system for eradicating a pre-cancerous esophageal ...
... And All Subsequent Study Visits - , , ... Ltd., (DSP) announced today that positive results from a phase ... with schizophrenia have been published in The Journal of ... involving 180 patients with acute schizophrenia, evaluated a single fixed ...
Cached Medicine Technology:Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons 2Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons 3Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons 4Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 4
(Date:7/11/2014)... 2014 The Europe Well Intervention Market report ... with analysis and revenue forecast. The well intervention services market ... in 2013 to $3.4 billion by 2018, at a CAGR ... TOC of the Europe Well Intervention Market report, to get ... a glimpse of the segmentation in the Europe well intervention ...
(Date:7/11/2014)... In people with sex addiction, pornography affects the brain ... drug addicts as they consume drugs, a new study ... between patients who have compulsive sexual behavior and healthy ... author Dr. Valerie Voon, of the University of Cambridge ... Voon,s research involved 19 men with sex addiction and ...
(Date:7/11/2014)... 11, 2014 The report “Probiotics ... Nutrients, Animal Feed), Applications (Regular, Therapeutic, Preventive Health ... Trends & Forecasts to 2019 ” defines and ... and forecasting of the market value of probiotic ... driving and restraining factors for the global market ...
(Date:7/11/2014)... Biostimulants are widely applied in turf and ... These also help turf and ornamentals in absorption of ... ornamentals, and flowers appear healthy and strong as a ... from the last few years. The most dominating region ... with around 40% share in 2013, and is estimated ...
(Date:7/11/2014)... 2014) Obese and overweight firefighters are not ... providers, according to new research from The University ... , National guidelines state that health care professionals ... maintaining a healthy weight. Firefighters have high rates ... cause of line-of-duty deaths in firefighters. This study ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... A problem in the lining of blood vessels may play ... a new study. The condition, called endothelial dysfunction, involves ... of cells that line blood vessels. Nitric oxide is crucial ... flow and the delivery of oxygen and nutrients to tissues. ...
... York, New YorkPremiums for employer-sponsored family health insurance increased ... to 2009, more than three times faster than median ... insurance is buying less. The report found that deductibles ... plus higher out-of-pocket costs are putting working families, budgets ...
... , WEDNESDAY, Dec. 1 (HealthDay News) -- Being exposed ... linked to dementia, a new study of agricultural workers suggests. ... who were in their 40s and 50s and had worked ... intellectual abilities were assessed twice, using nine tests designed to ...
... are nearly three times as likely as civilians to ... at Portland State University (PSU) and Oregon Health & ... Among Women With U.S. Military Service: A Hidden Epidemic?" ... Services , a journal published by the American Psychiatric ...
... By Kathleen Doheny HealthDay Reporter , WEDNESDAY, ... proven superior to other regimens for breast cancer that ... better for some women whose cancers haven,t spread, a ... these "node-negative" cancers, the drug combination of docetaxel, doxorubicin ...
... variations in a gene as important contributors to neuroblastoma, ... study team, led by researchers at The Children,s Hospital ... gene increase the risk of developing an aggressive form ... to drive the cancer,s progression once it forms. ...
Cached Medicine News:Health News:New Piece of Alzheimer's Puzzle Identified 2Health News:New report: Employer health insurance premiums increased 41 percent from 2003 to 2009 2Health News:New report: Employer health insurance premiums increased 41 percent from 2003 to 2009 3Health News:New report: Employer health insurance premiums increased 41 percent from 2003 to 2009 4Health News:Working With Pesticides May Affect Memory and More 2Health News:Suicide rate among young women veterans more than twice that of civilians 2Health News:Docetaxel May Boost Outcomes For Breast Cancers That Haven't Spread to Lymph 2Health News:Docetaxel May Boost Outcomes For Breast Cancers That Haven't Spread to Lymph 3Health News:New gene for childhood cancer neuroblastoma is discovered 2Health News:New gene for childhood cancer neuroblastoma is discovered 3
Designated most popular model or size. 4 mm wide tip....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
Medicine Products: